22 Jan In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property
Ed Silverman
STAT, 1/22/24...
Ed Silverman
STAT, 1/22/24...
Eileen McDermott
IPWatchdog, 1/18/24
...
Dave Allen
WSYR-AM, 1/10/24...
Steve Gruber
The Steve Gruber Show (WJIM-AM), 1/10/24...
Lars Larson
The Lars Larson Show, 1/9/24...
Gareth Macdonald
BioProcess Insider, 1/3/2024...
The Dispatch, 12/12/2023...
Eileen McDermott
IPWatchdog, 12/7/2023...
Nicole DeFeudis
Endpoints News, 12/7/2023...
Patrick Wingrove
Reuters, 12/7/2023...